CD70 and chronic myelogenous leukemia, BCR-ABL1 positive: Similarly, in chronic myeloid leukaemia, imatinib, a tyrosine kinase inhibitor (TKI), was found to upregulate CD70 expression on LSCs via epigenetic mechanisms, and combining anti‐CD70 antibodies with TKIs effectively eliminated resistant LSCs by disrupting compensatory CD70/CD27‐mediated Wnt signalling.133